The Europe Oral Antiviral Market should witness market growth of 1.9% CAGR during the forecast period (2023-2029).
People are receiving guidance about viral infections, including hepatitis and influenza, from several groups and the government. Due to consumers' increasing preference for online buying over conventional purchasing methods, e-commerce (or electronic commerce) has emerged as a crucial tool for small and large enterprises worldwide. The market has grown due to various animations used in health apps to inform individuals about HIV infection and medication use. In addition to established nations, developing nations are also showing a desire for potent oral antiviral medications, which is what is driving the market's expansion. In addition, it is anticipated that increased manufacturer promotional efforts and rising public awareness of the need to treat viral infections properly will accelerate the adoption of these technologies in the coming years.
One of the key factors anticipated to drive the growth of the market is the increased prevalence of viral disorders. Growing research funding to create a therapy option that works with ongoing clinical trials is anticipated to drive market expansion. In addition, the top businesses are engaging in mergers and acquisitions to expand the range of treatments available using cutting-edge discoveries like breakthrough immunotherapy medications or other unique formulations.
In Russia, each person spent an average of $140 on prescription drugs in 2018. In the same year, Russia sold over $20.1 billion of pharmaceuticals, accounting for 1.2% of the GDP and 22.1% of the country's total health expenditures. Both prescription and over-the-counter (OTC) medications fall within the pharmaceutical industry in Russia. In general, sales of prescription drugs dominate the pharmaceutical industry, which persisted in 2018 prescription drugs.
The world's largest cooperative healthcare system was established in 1948 with the National Health Services (NHS). It was established to offer healthcare to all individuals and is accessible to all UK residents. The NHA assigns an entity to manage the efficient use of more than £100 billion in funding to commission medical services in England. The expanding pharmaceutical sector and the rising funding will surge investment in the market in the Europe region.
The Germany market dominated the Europe Oral Antiviral Market by Country in 2022 thereby, achieving a market value of $2,673.4 million by 2029. The UK market is showcasing a CAGR of 1.1% during (2023-2029). Additionally, The France market would register a CAGR of 2.7% during (2023-2029).
Based on Indication, the market is segmented into Human Immunodeficiency Virus (HIV), Hepatitis, Influenza and Others. Based on Drug Class, the market is segmented into Reverse Transcriptase Inhibitors, Protease Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., Viatris, Inc. (Mylan N.V.), AbbVie, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceutical Industries Ltd., and Amneal Pharmaceuticals, Inc.
People are receiving guidance about viral infections, including hepatitis and influenza, from several groups and the government. Due to consumers' increasing preference for online buying over conventional purchasing methods, e-commerce (or electronic commerce) has emerged as a crucial tool for small and large enterprises worldwide. The market has grown due to various animations used in health apps to inform individuals about HIV infection and medication use. In addition to established nations, developing nations are also showing a desire for potent oral antiviral medications, which is what is driving the market's expansion. In addition, it is anticipated that increased manufacturer promotional efforts and rising public awareness of the need to treat viral infections properly will accelerate the adoption of these technologies in the coming years.
One of the key factors anticipated to drive the growth of the market is the increased prevalence of viral disorders. Growing research funding to create a therapy option that works with ongoing clinical trials is anticipated to drive market expansion. In addition, the top businesses are engaging in mergers and acquisitions to expand the range of treatments available using cutting-edge discoveries like breakthrough immunotherapy medications or other unique formulations.
In Russia, each person spent an average of $140 on prescription drugs in 2018. In the same year, Russia sold over $20.1 billion of pharmaceuticals, accounting for 1.2% of the GDP and 22.1% of the country's total health expenditures. Both prescription and over-the-counter (OTC) medications fall within the pharmaceutical industry in Russia. In general, sales of prescription drugs dominate the pharmaceutical industry, which persisted in 2018 prescription drugs.
The world's largest cooperative healthcare system was established in 1948 with the National Health Services (NHS). It was established to offer healthcare to all individuals and is accessible to all UK residents. The NHA assigns an entity to manage the efficient use of more than £100 billion in funding to commission medical services in England. The expanding pharmaceutical sector and the rising funding will surge investment in the market in the Europe region.
The Germany market dominated the Europe Oral Antiviral Market by Country in 2022 thereby, achieving a market value of $2,673.4 million by 2029. The UK market is showcasing a CAGR of 1.1% during (2023-2029). Additionally, The France market would register a CAGR of 2.7% during (2023-2029).
Based on Indication, the market is segmented into Human Immunodeficiency Virus (HIV), Hepatitis, Influenza and Others. Based on Drug Class, the market is segmented into Reverse Transcriptase Inhibitors, Protease Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., Viatris, Inc. (Mylan N.V.), AbbVie, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceutical Industries Ltd., and Amneal Pharmaceuticals, Inc.
Scope of the Study
By Indication
- Human Immunodeficiency Virus (HIV)
- Hepatitis
- Influenza
- Others
By Drug Class
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Others
By Distribution Channel
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Gilead Sciences, Inc.
- Viatris, Inc. (Mylan N.V.)
- AbbVie, Inc.
- GlaxoSmithKline PLC (GSK)
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Europe Oral Antiviral Market by Indication
Chapter 4. Europe Oral Antiviral Market by Drug Class
Chapter 5. Europe Oral Antiviral Market by Distribution Channel
Chapter 6. Europe Oral Antiviral Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Gilead Sciences, Inc.
- Viatris, Inc. (Mylan N.V.)
- AbbVie, Inc.
- GlaxoSmithKline PLC (GSK)
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
Methodology
LOADING...
